MedTrace Logo

Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

NCT00127881 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2012-07-26

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin® and one other standard therapy.

Conditions

  • Mycosis Fungoides
  • Sezary Syndrome

Interventions

DRUG

HuMax-CD4 (zanolimumab)

Monoclonal Antibody, 12 weekly infusions.

Sponsors & Collaborators

  • Emergent Product Development Seattle LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2014-02-28

Countries

  • United States
  • France
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00127881 on ClinicalTrials.gov